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Background: Early diagnosis of delayed cerebral ischemia (DCI) in patients after
aneurysmal subarachnoid hemorrhage (aSAH) still poses a leading problem in
neurointensive care. The aim of this study was to analyze the effect of oral Nimodipine
administration on systemic blood pressure in patients with evolving DCI compared to
patients without DCI.
Methods: Systolic (SBP), mean (MAP), and diastolic (DBP) blood pressures were
analyzed at the time of Nimodipine administration and additionally 30, 60, and 120min
thereafter on days 1, 3, and 5 after aSAH. Additionally, the 24 h period preceding DCI
and in patients without DCI day 10 after aSAH were analyzed. Statistical analysis was
performed for SBP, MAP and DBP at time of Nimodipine administration and for the
maximal drop in blood pressure after Nimodipine administration.
Results: Thirty patients with aSAH were retrospectively analyzed with 17 patients
developing DCI (“DCI”) and 13 patients who did not (“Non-DCI”). DCI patients showed
a more pronounced rise in MAP and DBP over the examined time period as well as a
higher decrease in SBP following Nimodipine administration. A fall of 18 mmHg in SBP
after Nimodipine administration showed a sensitivity of 82.4% and specificity of 92.3%
for occurrence of DCI.
Conclusion: An increase of MAP and DBP after aSAH and a heightened sensitivity
to Nimodipine administrations may serve as additional biomarkers for early detection of
evolving DCI.
Keywords: blood pressure variability, cerebral vasospasm, hypertension, delayed cerebral ischemia, cerebral
infarction, cerebral perfusion, Nimodipine
INTRODUCTION
Cerebral vasospasm related ischemia remains the leading cause of disability for patients with
aneurysmal subarachnoid hemorrhage (aSAH) who survive the initial bleed and in whom the
ruptured aneurysm has been secured (1, 2). Reported incidences of vasospasm-associated cerebral
infarction reach up to 44% (3–5). Hence, early detection of evolving cerebral vasospasms and
looming misery perfusion is crucial.
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Several studies have reported that the L-type calcium
channel blocker Nimodipine lowers the incidence of cerebral
infarction and poor outcome in aSAH patients (6–9). The
British aneurysm Nimodipine trial (1989) showed that poor
outcome defined as death or severe disability was reduced by
40% in patients receiving 60mg Nimodipine orally every 4 h
for 21 days or until vasospasm occurred (8). Interestingly, the
drug was not shown to lower the incidence of angiographic
vasospasm. Therefore, it is hypothesized that the protective effect
mainly stems from a reduction of cortical spreading ischemia,
a decrease of microthrombi through fibrinolytic activity or
neuroprotection (10).
Earlier studies investigating blood pressure changes after
aSAH reported a more pronounced blood pressure rise in
patients developing severe cerebral vasospasm or DCI (11–13).
However, concerning the time point of blood pressure increase
the studies report controversial results. Whereas, Faust et al. (11)
and Teping et al. (13) found significant blood pressure differences
between groups within the first 4 days after the bleeding, Fontana
et al. (12) report differences only after day 8. Furthermore, the
use of Nimodipine differed between the studies and none of
the studies investigated the effect of Nimodipine application on
systemic blood pressure.
The aim of this study was to analyze systemic blood pressure
effects of orally administered Nimodipine in patients after
aSAH who develop clinically symptomatic cerebral vasospasm
compared with asymptomatic patients.
MATERIALS AND METHODS
This is a single-center retrospective case-control study of
patients with aSAH treated at the University Hospital Bern,
Bern, Switzerland. Patients aged >18 years and < 80 years
were included.
Study Design
Our prospectively conducted database for patients treated with
aSAH at the University Hospital Bern was retrospectively
searched. Patients hospitalized between July 2012 and October
2015 were included. Inclusion criteria were: (1) patients
were treated in the Intensive or Intermediate Care Unit;
(2) patients received 60mg Nimodipine orally every 4 h;
(3) no other vasoactive medication or analgosedation was
administered after aneurysm treatment; (4) patients had either
intra-arterial BP-monitoring or non-invasive BP-monitoring
at least every 30min; (5) patients had a Glasgow Coma
Scale (GCS) of >8 after aneurysm treatment (6) patients
had no hemodynamic impairments (e.g., preexisting coronary
impairments or Takotsubo cardiomyopathy).
Abbreviations: ANOVA, Analysis of Variance; aSAH, Aneurysmal Subarachnoid
Hemorrhage; CPP, Cerebral Perfusion Pressure; DBP, Diastolic Blood Pressure;
DCI, Delayed Cerebral Ischemia; GCS, Glasgow Coma Scale; HR, Heart rate; ICU,
Intensive Care Unit; IMC, Intermediate Care Unit; MAP, Mean Arterial Pressure;
NE, Norepinephrine; NIHSS, National Institutes of Health Stroke Scale; RASS,
Richmond Agitation Sedation Scale; ROC, Receiver-Operating Characteristic;
SAH, Subarachnoid Hemorrhage; SBP, Systolic Blood Pressure.
Patients were divided into two groups, those who developed
DCI (“DCI”) and those who did not (“Non-DCI”). DCI was
defined as acute occurring neurological deficit fulfilling the
following criteria: (i) decrease of GCS and/or increase of the
National Institutes of Health Stroke Scale of at least 2 points
for ≥1 h; (ii) exclusion of other causes for neurological
deterioration (including epileptic seizure, intracerebral
bleeding, hydrocephalus, infection, metabolic causes), and
(iii) confirmation of hypoperfusion in a perfusion CT.
Data Collection
Data was extracted from the institutional electronic Patient
Data Management System (CentricityTM Critical Care, General
Electric Company, GE Healthcare, United States of America).
The system automatically documents all hemodynamic variables
in intervals of 2min. Further data such as clinical scores, fluid
balances and administered drugs are entered manually by the
bedside team.
Systolic (SBP), mean arterial (MAP), and diastolic (DBP)
blood pressure values and heart rate (HR) were assessed at the
time point of every single Nimodipine administration (t0) and
additionally 30, 60, and 120min thereafter. All variables were
recorded for the 6 Nimodipine administrations at day 1, 3, and
5 after aneurysm treatment, and Nimodipine administrations
24 h prior to DCI or at day 10 in Non-DCI patients (= day
preceding event). In addition, GCS and Richmond Agitation
Sedation Scale (RASS) scores were assessed at t0for the above-
mentioned time points. The history of preexisting hypertension
was directly extracted from the patient medical records.
Statistical Analysis
For each Nimodipine administration the maximal change of SBP
at 30, 60 or 120min compared to t0 was calculated. The maximal
change was used for further statistical analysis. The same time
point was chosen for calculation of MAP, DBP and HR changes.
SBP, MAP, DBP, and HR values at t0, as well as the maximal
change after Nimodipine administration were averaged for each
analyzed day. GCS and RASS at t0 were also averaged for each
analyzed day.
Statistical analyses were performed using SPSS Statistics
21.0 (IBM, Armonk, NW, USA) and Stata 16 (StataCorp.
2019. Stata Statistical Software: Release 16. College Station, TX:
StataCorp LLC.). The Shapiro–Wilk normality test was used to
test for normal distribution. Unpaired t-test was used to test
for significant differences of metric variables between the DCI
and Non-DCI groups. Chi-squared test was used to determine
potential differences in sex, history of hypertension and method
of aneurysm treatment. For hemodynamic variables, GCS and
RASS, a mixed effect model for repeatedmeasures was performed
to test the interaction between group and days. In addition,
an adjusted model for age and gender was performed. Data
are presented as mean ± standard deviation (SD) or in figures
as mean ± standard error of the mean (SEM). A p < 0.05
was considered statistically significant. Diagnostic threshold
values for blood pressure changes were calculated using receiver
operator characteristics (ROC) curves. From the ROC curves,
optimal threshold values to distinguish between patients with and
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TABLE 1 | Patient characteristics.
Non-DCI DCI p-value
Number of Patients 13 17
Median age (years, range) 56(38–79) 56(36–70) 0.463#
Sex 0.091+
Female 7 (54%) 14 (82%)
Male 6 (46%) 3 (18%)
History of Hypertension 5 (38%) 5 (29%) 0.602+
BNI Score
1 0 (0%) 0 (0%)
2 4 (31%) 0 (0%)
3 3 (23%) 5 (47%)
4 4 (31%) 4 (24%)
5 2 (15%) 5 (29%)
Fisher Score
1 0 (0%) 0 (0%)
2 1 (6%) 0 (0%)
3 10 (77%) 16 (94%)
4 2 (15%) 1 (6%)
Aneurysm Location
ICA 2 (15%) 0 (0%)
MCA 1 (8%) 2 (12%)
ACOM 5 (38%) 5 (29%)
ACA 0 (0%) 0 (0%)
VA 0 (0%) 2 (12%)
PICA 1 (8%) 0 (0%)
SCA 0 (0%) 1 (6%)
Basilar 0 (0%) 2 (12%)
A. pericallosa (A2) 1 (8%) 1 (6%)
PICOM 3 (23%) 4 (24%)
Aneurysm Treatment
Clipping 1 (8%) 3 (18%) 0.249+
Coiling 12 (92%) 13 (76%) 0.427+
Values represent the number of patients with their respective percentages in brackets.
# Independent samples t-test. +Chi-squared test.
without DCI were derived by seeking the best tradeoff between
highest possible sensitivities and specificities.
RESULTS
Patient Characteristics
From July 2012 to October 2015, 224 patients were treated for
aSAH in the ICU or IMC at the University Hospital of Bern,
Bern, Switzerland. One hundred and ninety-four patients were
excluded because they did not meet the inclusion criteria. Main
reasons for exclusion were either missing blood pressure data for
distinct time points or treatment with vasoactive medication. The
final study population was composed of 17 patients in the DCI
and 13 patients in the Non-DCI group. Table 1 shows clinical
characteristics of both patient groups. Although there were no
statistical differences between the two groups when comparing
age, sex, history of hypertension, method of aneurysm treatment
or BNI and Fisher scores, there was a tendency for a higher
percentage of female patients in the DCI group. In agreement
with other publications, the aneurysms were primarily located in
ACOM and PICOM (14).
Hemodynamic Changes at Time of
Nimodipine Administration (t0)
Blood pressure levels at t0 increased over the analyzed time
period in both patient groups (Figures 1A–C, Table 2). However,
the increase of blood pressure was more prominent in patients
of the DCI group when compared to patients without DCI.
ANOVA for repeated-measures revealed a significant interaction
of group∗time course for MAP (p = 0.027) and marginally
for DBP (p = 0.049) but not for SBP (p = 0.092). When
adjusting for sex and age, the interaction for SBP also reached
significance (p = 0.011), whereas DBP was not significant
anymore (p= 0.061). Adjustment did not change the significance
level for MAP (p = 0.023). There were no significant changes in
HR, GCS, and RASS values over the observation period.
Nimodipine-Induced Hemodynamic
Changes
In both groups, there was a dip in systemic blood pressure after
Nimodipine application (Figures 1D–F, Table 2). However, the
dip in blood pressure became more prominent during the course
of disease in patients developing DCI compared to patients who
did not. This effect was most prominent for SBP (p = 0.037).
After correction for sex and age, this effect proved to be even
more prominent (p < 0.001). HR remained unchanged in both
groups after Nimodipine application.
Threshold Values for Predicting DCI
Table 3 shows diagnostic threshold values for MAP and DBP
changes at t0 as well as for Nimodipine induced SBP dips. A
Nimodipine induced SBP drop of−18mmHg showed the highest
sensitivity and specificity for predicting DCI.
DISCUSSION
In this retrospective study we analyzed systemic blood
pressure changes in patients with aSAH after aneurysm
treatment receiving Nimodipine orally every 4 h. At time of
Nimodipine administration (t0), MAP, and DBP increased
significantly in patients developing DCI when compared to
clinically asymptomatic patients. Additionally, a heightened
responsiveness of SBP to Nimodipine in patients developing DCI
was found.
Systemic Blood Pressure Rise at Time of
Nimodipine Administration (t0)
Three previous studies already investigated systemic blood
pressure changes after aSAH. All reported a more pronounced
systemic blood pressure increase in patients developing severe
angiographic vasospasm or DCI (11–13). However, the time
point of blood pressure increase differed between these studies.
Whereas, Faust et al. (11) and Teping et al. (13) reported
a significant blood pressure increase in patients developing
severe vasospasms or DCI already within the first 4 days
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FIGURE 1 | Bar graphs showing systemic blood pressure at t0 and maximal blood pressure changes after Nimodipine administration in patients with evolving delayed
cerebral ischemia (DCI, white) and patients without DCI (Non-DCI, gray). (A) Systolic (SBP), (B) mean arterial (MAP), and (C) diastolic (DBP) blood pressures at time of
Nimodipine administration (t0). (D) SBP, (E) MAP, and (F) DBP changes after Nimodipine administration. Event = day preceding DCI or day 10 in patients without DCI.
Mean ± Standard error of the mean.
after bleeding, Fontana et al. (12) found differences only after
day 8. Only the studies by Fontana et al. (12) and Teping
et al. (13) included patients treated with Nimodipine but
did not investigate the effect of Nimodipine application on
blood pressure. We only enrolled patients who received 60mg
Nimodipine orally every 4 h and used a clinical endpoint for
DCI. In parallel to the earlier studies, our study also shows
an increase of systemic blood pressure after aSAH, which was
more pronounced for MAP and SBP in patients who develop
DCI. The findings of the previous and our own study suggest
an association between development of cerebral vasospasms
or DCI and spontaneous blood pressure rise. In fact, it has
been shown that sympathetic activation increases after aSAH
in patients with evolving cerebral vasospasms (15, 16). To
maintain cerebral blood flow constant in the face of narrowing
cerebral vessels, the brain has to increase cerebral perfusion
pressure. This is mediated by sympathetic activation and rise
of endogenous catecholamine release leading to an increase of
peripheral resistance and therefore a rise of MAP and cerebral
perfusion pressure, respectively (17). The smaller increase of
MAP and DBP in the Non-DCI group is most likely due to
milder sympathetic activation because of less severe, clinically not
relevant vasospasms.
Drop in Systemic Blood Pressure After
Nimodipine Administration
The L-type calcium channel blocker Nimodipine has a strong
vasodilating effect. Interestingly, SBP drops after Nimodipine
application more pronounced in patients with evolving DCI.
Earlier studies showed contradictory effects of Nimodipine
on catecholamine action and sympathetic nervous system
tone (18–23). It has been postulated that Nimodipine affects
norepinephrine (NE) mediated contraction of blood vessels,
postsynaptic adrenoceptors and lowers plasma catecholamine
concentrations. One hypothesis for the more prominent dip
of SBP in patients with evolving DCI might be that DCI
patients experience a higher sympathetic nervous tonus and a
surge in NE to sustain brain tissue perfusion. Therefore, they
have likely reached maximum capacity of their endogenous NE
levels and are subsequently more susceptible to the effect of
Nimodipine (16, 24, 25). It is still unclear why the blood pressure
drop was significant for SBP but not for MAP and DBP. A
possible explanation was reported by Van Meel et al. (20) who
showed in a rat model that Nimodipine helped to block out
the effects of NE on SBP but not on DBP. Hence, patients
with impending DCI and consequently higher endogenous NE
levels would therefore show a greater fall in SBP than patients
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TABLE 2 | Systemic blood pressure and heart rate at time of Nimodipine administration (t0), Nimodipine associated hemodynamic changes, and clinical assessment.
Day 1 Day 3 Day 5 Day preceding DCI p-value p-value adjusted
(sex, age)
Non-DCI DCI Non-DCI DCI Non-DCI DCI Non-DCI DCI
SBP (mmHg) 137.3 ± 12.1 136.3 ± 18.7 149.9 ± 21 150.4 ± 21.8 150.7 ± 24.7 163.1 ± 21.6 149.8 ± 23.1 163.4 ± 20.7 0.092 0.011*
MAP (mmHg) 91.3 ± 7.1 90.9 ± 11.3 100.8 ± 15.4 97.7 ± 13.5 100.2 ± 12.9 107.7 ± 14.9 101.6 ± 9.7 108.9 ± 11.6 0.027* 0.023*
DBP (mmHg) 65.2 ± 6.1 65 ± 7.6 73.5 ± 12.8 69.4 ± 10.1 73.3 ± 10.8 78 ± 11.5 74.3 ± 7.1 78.7 ± 8.7 0.049* 0.061
HR (bpm) 71.8 ± 11.1 67.9 ± 10.3 73.7 ± 11.5 66.7 ± 11.2 73.9 ± 14 71.3 ± 10.6 77.1 ± 12.4 76.7 ± 12 0.374 0.636
SBP dip (mmHg) −12.4 ± 4.6 −11.4 ± 5.3 −13.1 ± 4.8 −15.4 ± 4.4 −12.6 ± 5.6 −19.2 ± 7.4 −14.1 ± 7.4 −22.3 ± 7.1 0.037* <0.001*
MAP dip (mmHg) −8 ± 3 −7.3 ± 3.5 −9.5 ± 4.3 −8.9 ± 3.4 −10.1 ± 6.8 −10 ± 4.4 −9.6 ± 3.3 −12.6 ± 4.3 0.169 0.129
DBP dip (mmHg) −5.6 ± 2.5 −5.4 ± 3 −7.6 ± 3.4 −6 ± 3.1 −8 ± 8.1 −6 ± 5.6 −7.8 ± 3.7 −9.3 ± 2.4 0.427 0.946
HR dip (bpm) 1 ± 3 −1.3 ± 5.2 1.2 ± 4.7 1.8 ± 4.6 1.1 ± 4.3 1.8 ± 4.1 0.4 ± 4.0 0.1 ± 5.6 0.970 0.936
GCS 12.2 ± 2.4 11.9 ± 2.5 13.1 ± 1.4 12.9 ± 1.8 13.5 ± 1.3 13.9 ± 1.1 13.9 ± 1 13.3 ± 1.8 0.162 0.950
RASS −0.6 ± 1 −1.1 ± 1.3 −0.3 ± 0.8 −0.8 ± 0.9 −0.5 ± 1 −0.2 ± 0.8 0.1 ± 0.8 −0.3 ± 0.9 0.161 0.590
Values represent means ± Standard deviation. *p ≤ 0.05 DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure.
without DCI in response to Nimodipine. The effect of NE onDBP
would remain uninfluenced by Nimodipine, resulting in non-
significant blood pressure differences in MAP and DBP between
the two groups. In a recent paper published by Kieninger et al.
(26) studying the incidence of arterial hypotension in patients
treated with Nimodipine after aSAH and perimesencephalic
SAH, episodes of hypotension after Nimodipine administration
were predominantly found if the drug was given orally in
patients with higher-grade SAH. Furthermore, an association was
found between a lower risk of unfavorable outcome and patients
who showed less episodes of hypotension after Nimodipine
administration. As DCI is the leading cause of unfavorable
outcome in patients with SAH who survive the initial bleed, the
findings of the study by Kieninger et al. indirectly support the
findings of our study. However, contrary to the present study,
Nimodipine dosages were reduced or stopped on over 40% of the
examined days, whereas in our analysis, only patients receiving
the full Nimodipine dosages were enrolled.
There have been other studies analyzing blood pressure
variability in relationship with different outcome measurements
after aSAH (27–31). Even though all of those studies established
a higher blood pressure variability to be associated with worse
scores in the examined parameters, their results cannot be
directly compared with those of the present study due to different
study designs.
Prediction of DCI in Clinical Practice
Our data shows that distinct changes of systemic blood pressure
have sensitivities and specificities as high as 88.2 and 92.3%,
respectively for prediction of DCI. Reported sensitivities and
specificities for imaging are comparable (transcranial Doppler:
sensitivity 90%, specificity 71%; CT perfusion imaging: sensitivity
74–93%, specificity 63–93%) (32–40) or even lower (CT
angiography: sensitivity 64%, specificity 50%) (35). Hence,
bedside pattern recognition of evolving systemic blood pressure
alterations may serve as an easy clinical tool for early detection
of looming DCI in patients after aSAH which complements
TABLE 3 | AUCs with corresponding 95% CIs of changes in mean and diastolic
blood pressure at t0 and drops of systolic pressure after Nimodipine
administration, as well as sensitivities and specificities for the detection of DCI.
AUC (95% CI) Threshold (mmHg) Sensitivity Specificity
MAP change 0.719 (0.524–0.915) 15 0.765 0.769
DBP change 0.719 (0.524–0.915) 11 0.882 0.615
SBP dip 0.799 (0.614–0.983) −18 0.824 0.923
AUC, area under the curve; CI, confidence interval; DBP, diastolic blood pressure; MAP,
mean arterial pressure; SBP, systolic blood pressure.
imaging. The use of an electronic patient data management
system supports pattern recognition.
Limitations
The retrospective and single center study design represents
the major limitation of this study. Additionally, only a small
cohort of all patients treated for aSAH in our hospital could
finally be enrolled into the study because of the very restrictive
inclusion criteria. The major reasons for exclusion of patients
were missing blood pressure data points or treatment with
vasoactive medication (either catecholamines of blood pressure
lowering drugs) after securing the aneurysm. In our opinion
the use of well-defined and restrictive inclusion criteria bears
the advantage of minimizing the natural bias of a retrospective
study design to some extent. The findings of this study have to
be verified with a prospective study design. Furthermore, the
calculated threshold values for prediction of DCI also need to be
verified with a prospective study.
CONCLUSION
Our results show that an increase of systemic blood pressure
after aSAH and a heightened sensitivity to Nimodipine
administrations may serve as additional biomarkers for
early detection of evolving DCI. Especially, SBP drops after
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Nimodipine administration, along with an overall rise in MAP
and DBP can point toward an increased risk for DCI.
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